| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department for Obstetrics and Gynecology,
Interdisciplinary Center for Clinical Research, and
Clinical research group KFO 124, University of Würzburg, Würzburg, Germany;
Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany;
¶ Department of Medicine and
|| Department of Pathology, Yale University School of Medicine, New Haven, CT 06520; and
# Department of Neurology, University Hospital Zurich, Zurich, Switzerland
The proinflammatory cytokine macrophage migration inhibitory factor (MIF) stimulates tumor cell proliferation, migration, and metastasis; promotes tumor angiogenesis; suppresses p53-mediated apoptosis; and inhibits antitumor immunity by largely unknown mechanisms. We here describe an overexpression of MIF in ovarian cancer that correlates with malignancy and the presence of ascites. Functionally, we find that MIF may contribute to the immune escape of ovarian carcinoma by transcriptionally down-regulating NKG2D in vitro and in vivo which impairs NK cell cytotoxicity toward tumor cells. Together with the additional tumorigenic properties of MIF, this finding provides a rationale for novel small-molecule inhibitors of MIF to be used for the treatment of MIF-secreting cancers.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by grants from the Interdisciplinary Center for Clinical Research Würzburg (to J.W.) and the National Institutes of Health (to L.L. and R.B.).
2 Address correspondence and reprint requests to Dr. Jörg Wischhusen, Interdisciplinary Center for Clinical Research Junior Research Group "Tumor Progression and Immune Escape," Department of Gynecology, University of Würzburg, Josef-Schneider-Strasse 4, D-97080 Würzburg, Germany. E-mail address: Wischhusen_J{at}klinik.uni-wuerzburg.de
3 Abbreviations used in this paper: OvCA, ovarian carcinoma; MIF, macrophage migration inhibitory factor; NKG2D, natural killer group 2D; SFI, specific fluorescence intensity; SN, supernatant; rh, recombinant human.
This article has been cited by other articles:
|
|
 |
|
  M. Carlsten, H. Norell, Y. T. Bryceson, I. Poschke, K. Schedvins, H.-G. Ljunggren, R. Kiessling, and K.-J. Malmberg Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells J. Immunol., October 15, 2009; 183(8): 4921 - 4930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Reim, Y. Dombrowski, C. Ritter, M. Buttmann, S. Hausler, M. Ossadnik, M. Krockenberger, D. Beier, C. P. Beier, J. Dietl, et al. Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells Cancer Res., October 15, 2009; 69(20): 8058 - 8066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Prieto-Lafuente, W. F. Gregory, J. E. Allen, and R. M. Maizels MIF homologues from a filarial nematode parasite synergize with IL-4 to induce alternative activation of host macrophages J. Leukoc. Biol., May 1, 2009; 85(5): 844 - 854. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
